Supplements
Download PDF
Sagar Lonial, MD
Lillian Chou, PharmD
Charise Gleason, MSN, ANP-BC, AOCNP
Cindy Ippoliti, PharmD
Lisa C. Smith, MSN, FNP, AOCN

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: November 24th, 2008 - November 24th, 2009

This activity is no longer available for credit, however its content is still relevant for your educational needs.

Target Audience
This educational publication is designed for physicians, nurses, and pharmacists who wish to enhance their knowledge concerning the management of side effects associated with multiple myeloma therapy.

Learning Objectives
At the completion of this activity participants should be able to:

  • Summarize the most common side effects associated with novel agents used in the treatment of multiple myeloma (MM)
  • Identify the side effects associated with these agents in various combination regimens
  • Discuss appropriate management strategies for MM patients experiencing treatment-related side effects and disease-related complications


Disclosure Statement
In direct response to the September 2004 ACCME Standards for Commercial Support, CME Consultants issued a conflict of interest policy dated January 2, 2005. The policy states that the disclosure of potential financial conflicts of interest within the last 12 months must be made and resolved prior to the date of the CME/CE activity where commercial support grants are to be used to fund the activity. The following conflicts have been managed and resolved through CME Consultants Independent Review Committee. Our intent is to assist learners in assessing the potential for bias in information that is presented during the CME/CE activity. The faculty is also aware it is their responsibility to inform the audience if discussion of any non-FDA-approved uses of pharmaceutical, medical equipment, prostheses, etc will be included in their presentation.

Faculty Disclosures
*Sagar Lonial, MD, is a consultant for Bristol-Myers Squibb, Celgene, Millennium, and Novartis, and has received research support from Bristol-Myers Squibb, Celgene, Gloucester, Millennium, and Novartis.

Lillian Chou, PharmD has nothing to disclose.

Charise Gleason, MSN, ANP-BC, AOCNP, is a consultant for Merck and Millennium.

Cindy Ippoliti, PharmD, is on the speaker’s bureau for Eisai and Schering-Plough.

Lisa Smith, MSN, FNP, AOCN is a speaker for Celgene, Medtronic, Millennium, and Novartis.


*Content will include non-FDA-approved uses.

Disclaimer
The contents of some CME activities may contain discussion of off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Related Items
Considerations in Multiple Myeloma Ask the Experts: Side Effect Management
Ruben Niesvizky, MD, Faiza Zafar, RPA-C, MPA, Cindy Ippoliti, PharmD
Supplements published on December 21, 2011
Considerations in Multiple Myeloma Ask the Experts: Newly Diagnosed Patients
Jonathan L. Kaufman, MD , Charise Gleason, MSN, ANP-BC, AOCNP, R. Donald Harvey, PharmD, FCCP, BCPS, BCOP
Supplements published on March 31, 2011
Considerations in Non-Hodgkin Lymphoma: Case Studies in Follicular Lymphoma
Peter Martin, MD, Alison Parker, PA, Cindy Ippoliti, PharmD
Supplements published on May 13, 2010
Considerations in Multiple Myeloma: Case Studies in Front-line Therapy
Katherine Sanvidge Shah, PharmD, BCOP, Jonathan Kaufman, MD, Charise Gleason, MSN, ANP-BC, AOCNP, Nicole Wilson, PharmD, BCOP
Supplements published on February 17, 2010
Considerations in Multiple Myeloma: Sequencing Strategies
Sagar Lonial, MD, Ajai Chari, MD, Sidney V. Keisner, PharmD, Sachin R. Shah, PharmD, BCOP
Supplements published on November 16, 2009
Considerations in Multiple Myeloma: To Transplant or Not to Transplant...That Is the Question!
Sagar Lonial, MD, Joan Bladé, MD, Dareth N. Gilmore, MS, RN, CNP, Sandra Horowitz, PharmD, RPh
Supplements published on November 16, 2009
Considerations in Multiple Myeloma: Cytogenetic Testing
Sagar Lonial, MD, Steve Stricker, PharmD, MS
Supplements published on September 30, 2009
Considerations in Multiple Myeloma: Stem Cell Mobilization
Sagar Lonial, MD, William Bensinger, MD, Beth Faiman, RN, MSN, APRN, BC, AOCN
Supplements published on August 31, 2009
Considerations in Multiple Myeloma: Perspectives on Relevant End Points of Clinical Trials
Sagar Lonial, MD, Shaji Kumar, MD, Gail M. Sulski, RN, MS, FNP, AOCNP, Katherine Sanvidge Shah, PharmD, BCOP
Supplements published on July 14, 2009
Considerations in Multiple Myeloma: Do Complete Responses Correlate with Clinical Benefit?
Sagar Lonial, MD, Barbara B. Rogers, CRNP, MN, AOCN, ANP-BC, Jill M. Kolesar, PharmD, FCCP, BCPS
Supplements published on June 10, 2009
Last modified: March 24, 2014